Related Experiment Videos
Trimethoprim-sulfamethoxazole desensitization in AIDS
G Papakonstantinou1, H Füessl, R Hehlmann
1Medizinische Poliklinik Ludwig-Maximilians-Universität München.
Klinische Wochenschrift
|April 15, 1988
Summary
Trimethoprim-sulfamethoxazole (TMS) desensitization enabled Pneumocystis pneumonia (PCP) treatment in two of three AIDS patients with allergic reactions. This approach allowed for successful PCP prophylaxis, reducing reinfection risks.
Area of Science:
- Infectious Diseases
- Immunology
- Pharmacology
Background:
- Pneumocystis pneumonia (PCP) is a significant opportunistic infection in patients with Acquired Immunodeficiency Syndrome (AIDS).
- Trimethoprim-sulfamethoxazole (TMS) is a primary treatment for PCP, but allergic reactions can necessitate treatment discontinuation.
- High mortality rates and frequent reinfection underscore the need for effective, continuous PCP management, even with prior allergies.
Purpose of the Study:
- To evaluate the efficacy and safety of a slow oral desensitization protocol for Trimethoprim-sulfamethoxazole (TMS) in patients with AIDS and a history of allergic reactions to the drug.
- To determine if successful desensitization could enable long-term PCP prophylaxis in this patient population.
Main Methods:
- A gradual oral desensitization protocol was implemented over 16 days, starting with a low dose (0.4 mg/2 mg) and progressively increasing to the standard prophylactic dose (160 mg/800 mg twice daily).
- Three patients with AIDS and a history of TMS-induced allergic reactions, who had previously discontinued TMS treatment, were enrolled.
- The protocol involved daily dose escalations for the initial 9 days, followed by a maintenance phase.
Main Results:
- The TMS desensitization protocol was successfully completed in two out of the three patients.
- Successful desensitization allowed for the initiation and continuation of PCP prophylaxis in the two responsive patients.
- No adverse events were reported during the desensitization process in the successful cases.
Conclusions:
- Oral TMS desensitization is a viable strategy for managing patients with AIDS who require PCP treatment or prophylaxis but have experienced prior allergic reactions.
- This approach can overcome treatment limitations imposed by allergies, enabling effective PCP management and potentially reducing mortality and reinfection rates.
- Further studies with larger cohorts are warranted to confirm the long-term efficacy and safety of TMS desensitization in this vulnerable population.